Exelixis' (EXEL) revenue growth in the coming years is expected to be meaningfully ahead of market estimates, which are likely "too conservative" in peak sales of the Cabometyx and Zanzalintinib treatments, Morgan Stanley said in a note e-mailed Monday.
Morgan Stanley raised its revenue trajectory for Cabometyx after including potential sales from emerging indications. Exelixis' long-term guidance for Zanzalintinib calls for peak revenue of about $5 billion in 2033 versus unadjusted market consensus at nearly $2 billion, the firm said in a note to clients.
"Such a steep discount from [Wall Street] suggests the Zanza opportunity may yet to be meaningfully embedded in the stock price," Morgan Stanley said.
The firm upgraded Exelixis' stock to an overweight rating from equal-weight, with a new price target of $40, up from $30.
The company's shares were up 2.6% in recent trading.
Price: 33.22, Change: +0.84, Percent Change: +2.59
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。